|Expression of MGMT, hMLH1 and XRCC1 in Gastric Cancer Tissue and Their Clinical Significance
|LI Xiao-feng1, LIU Ai-yong2, LI Jia3
|1. Department of Comprehensive Medical Oncology, Baotou Cancer Hospital, Baotou, 014030, China;
2. Department of Radiotherapy, Baotou Cancer Hospital, Baotou, 014030, China
3. Immune Planning Division, Baotou Center for Disease Control and Prevention, Baotou, 014030, China,
| 1 Li Y, Yang Y, Lu Y, et al. Predictive value of CHFR and MLH1 methylation in human gastric cancer. Gastric Cancer, 2014. Epub ahead of print.
2 Fang Hangrong, Zheng Jianyun, Liu Bin, et al. Expression of XRCC1 and MGMT in gastric cancer. Mod Oncol, 2013, 21(2): 377-80.
3 Hu Y, Zhou M, Li K, et al. Two DNA repair gene polymorphisms on the risk of gastrointestinal cancers: a meta-analysis. Tumour Biol, 2014, 35(3):1715-25.
4 Xiong HL, Liu XQ, Sun AH, et al. Aberrant DNA methylation of P16, MGMT, hMLH1 and hMSH2 genes in combination with the MTHFR C677T genetic polymorphism in gastric cancer. Asian Pac J Cancer Prev, 2013, 14(5): 3139-42.
5 Ksiaa F, Ziadi S, Amara K, et al. Biological significance of promoter hypermethylation of tumor-related genes in patients with gastric carcinoma. Clin Chim Acta, 2009, 404(2): 128-33.
6 Song B, Ai J, Kong X, et al. Aberrant DNA Methylation of P16, MGMT, and hMLH1 Genes in Combination with MTHFR C677T Genetic Polymorphism in gastric cancer. Pak J Med Sci, 2013, 29(6):1338-43.
7 Kupčinskaitė-Noreikienė R, Skiecevičienė J, et al. CpG island methylation of the MLH1, MGMT, DAPK, and CASP8 genes in cancerous and adjacent noncancerous stomach tissues. Medicina (Kaunas). 2013, 49(8): 361-6.
8 Nakatsu Y, Hattori K, Hayakawa H, et al. Organization and expression of the human gene for O6-methytguanine-DNAmethyltrans-ferase. Mutat Res DNA Repair, 1993, 293(2): 119 -32.
9 Jin J, Xie L, Xie CH, et al. Aberrant DNA methylation of MGMT and hMLH1 genes in prediction of gastric cancer. Genet Mol Res, 2014, 13(2): 4140-5.
10 Cappelli E, Taylor R, Cevasco M, et al. Involvement of XRCC1 and DNA ligaseⅢgene products in DNA base excision repair. Biol Chem, 1999, 272(38): 23970-5.
11 Dulic A, Bates PA, Zhang X, et al. BRCT domain interactions in the heterodimeric DNA repair protein XRCC1-DNA ligas Ⅲ. Biochemistry, 2001, 40(20): 5906-13.
12 Esteller M,Herman J G. Cancer as an epigenetic disease:DNA methylation and chromatin alterations in human tumors. J Pathol, 2002, 196:1-7.
13 Hansson J, Martenhed G, Egyházi S, et al. Analysis of O6-methylguanine-DNA methyltransferase mRNA in fine needle biopsies from human melanoma metastases by reverse transcription and polymerase chain reaction. Eur J Cancer. 1996, 32A(13): 2319-26.
14 Bobola MS, Berger MS, Ellenbogen RG, et al. O6-Methylguanine-DNA methyltransferase in pediatric primary brain tumors: relation to patient and tumor characteristics. Clin Cancer Res, 2001, 7(3): 613-9.
15 Esteller M. Cancer epigenetics: DNA methylation and chromatin alter-ation in human cancer. Adu Exp Med Bio, 2003, 532: 39-49.
16 Ma S, Egyházi S, Martenhed G, et al. Analysis of O(6)-methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy. Melanoma Res, 2002, 12(4): 335-42.
17 Yousuf A, Bhat MY, Pandith AA, et al. MGMT gene silencing by promoter hypermethylation in gastric cancer in a high incidence area. Cell Oncol (Dordr). 2014, 37(4): 245-52.
18 Zekri AR, Bahnasy AA, Shoeab FE, et al (2014). Methylation of multiple genes in hepatitis C virus associated hepatocellular carcinoma. J Adv Res, 5, 27-40.
19 Fumagalli C, Della Pasqua S, Bagnardi V, et al. Prevalence and clinicopathologic correlates of O⁶-methylguanine-DNA methyltransferase methylation status in patients with triplenegative breast cancer treated preoperatively by alkylating drugs. Clin Breast Cancer. 2014, 14(4): 285-90.
20 Kohya N, Miyazaki K, Matsukura S, et al. Deficient expression of O(6)-methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma. Ann Surg Oncol. 2002, 9(4): 371-9.
21 Shi J, Zhang G, Yao D, et al. Prognosis significance of aberrant gene methylation in gastric cancer. Cancer Res, 2012, 2(1): 116-29.
22 Li G1, Hu F, Yuan F, Fan J, et al. Intronic and promoter polymorphisms of hMLH1/hMSH2 and colorectal cancer risk in Heilongjiang Province of China. J Cancer Res Clin Oncol. 2015, [Epub ahead of print].
23 Sun Z, Yu X, Wang H, et al. Clinical significance of mismatch repair gene expression in sporadic colorectal cancer. Exp Ther Med. 2014, 8(5): 1416-22.
24 Scartozzi M, Blanchi F, Rosati S, et al. Mutation of hMLH1 and hMSH2 in patient with suspected instability and abnormali-ties of mismatch repair protein expression. J Clin
Oncol, 2002, 20: 1203-8.
25 Xiao XQ, Gong WD, Wang SZ, et al. Polymorphisms of mismatch repair gene hMLH1 and hMSH2 and risk of gastric cancer in a Chinese population. Oncol Lett, 2012, 3(3): 591-8.
26 Teng Y, Dai D, Shen W, et al. Effect of methylation of hMLH1 gene promotor on stage tumorigenesis and progression of human gastric cancer. Chinese J Gastrointest Surg, 2015, 25, 18(2): 166-70.
27 Choi WS, Seo HS, Song KY, et al. Gastrokine 1 expression in the human gastric mucosa is closely associated with the degree of gastritis and DNA methylation. J Gastric Cancer.
28 Moghbeli M, Moaven O, Memar B, et al. Role of hMLH1 and E-cadherin promoter methylation in gastric cancer progression. J Gastrointest Cancer, 2014, 45(1): 40-7.
29 Wang C, Sun Y, Han R, et al. XRCC1 genetic polymorphisms and bladder cancer susceptibility: a metaanalysis. Urology, 2008, 72: 869-7.
30 Kiyohara C, Takayama K, Nakanishi Y. Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis. Lung Cancer, 2006,
31 Cheng XD, Lu WG, Wan XY, et al. The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advance cervical carcinoma. Clin Cancer Res, 2009, 28(1): 91.
32 Shen H, Xu Y, Qian Y, et al. Polymorphisms of the DNA repair gene XRCC1 and risk of gastric cancer in a Chinese population. Cancer, 2000, 88: 601-6.
33 Yoshihiko Kitajima, Kohji Miyazaki, Shiroh Matsukura, et al. Loss of expression of DNA repair enzymes MGMT, hMLH1 and h MSH2 during tumor progression in gastric cancer. The Gastric Cancer, 2003, 6: 86 -95.
34 Zhang H, Liang H, Zhang ZL, et al. Expressions and the clinical significance of MGMT,hMLH1 in human gastric carcinoma. Chin J Cancer Prev Treat, 2007, 14(8): 593-6.
||TAN Mi-duo. Research Progress of Translational Medicine in Breast Cancer[J]. Journal of International Translational Medicine, 2017, 5(2): 86-91.
||SHEN Bo, LU Jian-wei, ZHANG Yan, WU Yuan, YUAN Yuan, FENG Ji-feng. Research Progress of MicroRNAs in Gastric Cancer[J]. Journal of International Translational Medicine, 2017, 5(2): 71-79.
||Lukas Gietz, Benjamin Mayer. A Resampling Approach for Sample Size Estimation in Animal Experiments[J]. Journal of International Translational Medicine, 2017, 5(2): 53-62.
||QIAN Ting, HUANG Xin-en. Comparison of the Efficacy and Safety of Pemetrexed-Based Versus Paclitaxel-Based Chemotherapy as Third-Line Treatment for Patients with Advanced Breast Cancer[J]. Journal of International Translational Medicine, 2017, 5(2): 63-66.
||MAO Xiao-dong, ZHE Yi, CHEN Ya-jun, LIU Kang-sheng. Detection of Serum Anti-Müllerian Hormone Level for Women of Reproductive Age: A Cross-Sectional Study[J]. Journal of International Translational Medicine, 2017, 5(2): 67-70.
||LIU Yong-jun, ZHOU Yan. Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy[J]. Journal of International Translational Medicine, 2017, 5(2): 80-85.